Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Malcolm Spicer

US Consumer Health Managing Editor

Washington, DC
Malcolm has expertly covered the OTC drug and nutritional supplement industries and markets since 2006. He provides authoritative and highly analytical insight into how and why the US Food and Drug Administration regulates OTC drugs, including homeopathics, and nutritional supplement manufacturing and marketing and also how companies competing in these industries can most efficiently and effectively comply with FDA regulations, the cornerstone for their success.

Latest From Malcolm Spicer

NDAC Among US FDA Advisory Committees With Slot Open For Voting Consumer Representative

FDA asks for nominations for voting or non-voting consumer members of its advisory committees. Also wants to hear from consumer organizations interested in participating in selecting consumer representatives for its advisory committees or panels.

Advisory Committees Prescription To OTC Switch

Clear Eyes Production Problems Prestige Consumer Didn’t See Coming Leave Supply On Shelves ‘Spotty’

“Clear Eyes is a perfect example where we're dual-sourced and two facilities don't usually go down at the same time. This was just a quite an anomaly,” says CFO Christine Sacco, noting PCH works with more than 100 contract manufacturers.

OTC Drugs Supply Chain

Stabilizing Formula Business ‘First And Foremost’ For Perrigo To Reach Sustainable Growth

Perrigo’s adjusted operating income from formula business in 2023 was around half the $140m it expects. Level won’t be reached in 2024 but it’s “well on track to recapturing” that amount in 2025 and to “capturing all of that plus in 2026,” says CEO Patrick Lockwood-Taylor.

Business Strategies OTC Drugs

Church & Dwight Atoning For Gummy Vitamin Slump After Punishment From Supply Problems

Executives at recent investor conference offer explanations of what’s happened to sales of the brands in addition to describing the strategies and decisions which have driven company-wide average 6.3% annual net sales growth over the past 10 years.

Consumer Dietary Supplements

Herbalife Opens Direct Lines To President, Recalculates On Marketing To GLP-1 Patients

During recent investor conference, president Stephan Gratziani and CFO John DeSimone discuss Herbalife’s restructuring in addition to progress on digital transformation program and lack of progress on expectations for marketing to consumers prescribed GLP-1 drugs for weight loss.

Dietary Supplements Restructuring

Kenvue Makes Progress Transitioning From J&J Cash Stream To ‘Profitable Growth’ On Its Own

For Kenvue, 2023 “was really about separating from J&J” as a segment “mostly focused on profit and cash,” says CEO Thibaut Mongon. “But in 2024, you see a very different Kenvue in action.”

Consumer M & A
See All
UsernamePublicRestriction

Register